Patents Examined by Kahsay Habte
  • Triazolo-azepine derivatives
    Patent number: 11370802
    Abstract: The present invention relates to a compound of formula (I) wherein Ar is (II) or (II); R is CH3 or OCH3; or a pharmaceutically acceptable acid addition salt or a corresponding enantiomer thereof. The compounds are modulators of ?-secretase (A ?42) and may be useful for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: June 28, 2022
    Assignee: Hoffmann-La Roche, Inc.
    Inventor: Hasane Ratni
  • Pyridine compound substituted with azole
    Patent number: 11365192
    Abstract: The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: June 21, 2022
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroaki Tanaka, Madoka Kawamura, Makoto Hamada, Yohei Kobashi, Yuji Ito, Kazuaki Suzuki, Ayako Bohno, Kosuke Funayama
  • Non-catalytic substrate-selective, p38?-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
    Patent number: 11357781
    Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: June 14, 2022
    Assignees: University of Maryland, Baltimore, The United States of America as represented by The Department of Veterans Affairs
    Inventors: Paul S. Shapiro, Alexander D. MacKerell, Jr., Jeffrey D. Hasday
  • Thienopyrimidine derivatives as ACC inhibitors and uses thereof
    Patent number: 11352371
    Abstract: The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 7, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie G. Bates, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Brian J. Kirby, Yurong Lai, Michael L. Mitchell, Gregg M. Schwarzwalder, James G. Taylor, Ting Wang
  • Methods of preparing inhibitors of influenza viruses replication
    Patent number: 11345700
    Abstract: A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (X): or a pharmaceutically acceptable salt thereof with Compound (Y): in the presence of a palladium catalyst and a carbonate or phosphate base to form compound (Z): or a pharmaceutically acceptable salt thereof; and (b) deprotecting the Ts group of Compound (Z) to form Compound (1) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: May 31, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, William Aloysius Nugent, Vadims Dvornikovs, Peter Jamison Rose
  • Quaternary lactam compound and pharmaceutical use thereof
    Patent number: 11345679
    Abstract: A quaternary lactam compound of formula (I). The compound is used in the manufacture of a medicament for the treatment and/or prevention of thrombotic or thromboembolic disorders.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 31, 2022
    Assignee: SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD.
    Inventors: Shanghai Yu, Yan Feng, Shiqiang Li, Xiaolin Wang, Zhilong Hu, Yawen Ding, Feihong Dai, Qian He, Chaodong Wang
  • 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
    Patent number: 11344549
    Abstract: The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: May 31, 2022
    Inventors: Qiang Zhang, Yansheng Liu, Lantao Li, Xingfu Li, Chenming Hu
  • Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
    Patent number: 11345676
    Abstract: Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 31, 2022
    Assignee: PHARMAKEA, INC.
    Inventor: Martin W. Rowbottom
  • Aliphatic acid amide derivative
    Patent number: 11339151
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: May 24, 2022
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Yuki Fujii, Masayuki Sakuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
    Patent number: 11325900
    Abstract: A novel class of inhibitors of protein kinases useful in the treatment of proliferative cell diseases and conditions including cancers, and especially those characterised by over-expression of CDK8 and/or one or more aberrant CDK8 activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure I.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: May 10, 2022
    Assignee: AUCENTRA HOLDINGS PTY LTD
    Inventors: Shudong Wang, Stephen Philip, Mingfeng Yu
  • Antibacterial compounds, compositions thereof, and methods using same
    Patent number: 11325920
    Abstract: The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 10, 2022
    Assignee: The Rockefeller University
    Inventors: Sean Brady, James Peek
  • Ketone inhibitors of lysine gingipain
    Patent number: 11325884
    Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: May 10, 2022
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
  • Compounds, compositions, methods for treating diseases, and methods for preparing compounds
    Patent number: 11312690
    Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 26, 2022
    Assignee: University of Lousville Research Foundation, Inc.
    Inventors: Geoffrey J. Clark, John O. Trent, Joseph A. Burlison, Nagaraju Miriyala
  • Compounds, compositions and methods
    Patent number: 11306077
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: April 19, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Phenylacetamides as inhibitors of rock
    Patent number: 11306081
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 19, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto
  • Crystalline form of a BACE inhibitor, compositions, and use
    Patent number: 11306080
    Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 19, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Laura M. Artino, William Morris, Eric Sirota, Richard J. Varsolona
  • Pesticidal compositions and methods
    Patent number: 11297838
    Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the structure of Formula A.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: April 12, 2022
    Assignee: CORTEVA AGRISCIENCE LLC
    Inventors: Natalie C. Giampietro, David Demeter, Lindsey G. Horty, Gary D. Crouse, Thomas C. Sparks
  • Benzimidazole and indole compounds and uses thereof
    Patent number: 11299473
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 12, 2022
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Minh Nguyen, Alexander Sokolsky, Oleg Vechorkin, Qinda Ye, Wenqing Yao
  • Thiazole compounds as protein kinase inhibitors
    Patent number: 11299489
    Abstract: Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: wherein R1 and R2 are defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: April 12, 2022
    Assignees: National Health Research Institutes, Taivex Therapeutics Corporation
    Inventors: Weir-Torn Jiaang, Yu-Sheng Chao
  • Five membered-aminoheterocycle and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
    Patent number: 11299488
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 12, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Tarun Kumar Maishal